These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 23163768)

  • 1. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.
    Juliano RL; Carver K; Cao C; Ming X
    J Drug Target; 2013 Jan; 21(1):27-43. PubMed ID: 23163768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology.
    Juliano RL; Ming X; Carver K; Laing B
    Nucleic Acid Ther; 2014 Apr; 24(2):101-13. PubMed ID: 24383421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis.
    Ming X
    Expert Opin Drug Deliv; 2011 Apr; 8(4):435-49. PubMed ID: 21381985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.
    Juliano R; Alam MR; Dixit V; Kang H
    Nucleic Acids Res; 2008 Jul; 36(12):4158-71. PubMed ID: 18558618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't.
    Juliano RL
    Nucleic Acid Ther; 2018 Jun; 28(3):166-177. PubMed ID: 29708838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides.
    Juliano RL; Ming X; Nakagawa O
    Bioconjug Chem; 2012 Feb; 23(2):147-57. PubMed ID: 21992697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disulfide-Unit Conjugation Enables Ultrafast Cytosolic Internalization of Antisense DNA and siRNA.
    Shu Z; Tanaka I; Ota A; Fushihara D; Abe N; Kawaguchi S; Nakamoto K; Tomoike F; Tada S; Ito Y; Kimura Y; Abe H
    Angew Chem Int Ed Engl; 2019 May; 58(20):6611-6615. PubMed ID: 30884043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.
    Fattal E; Bochot A
    Int J Pharm; 2008 Dec; 364(2):237-48. PubMed ID: 18619528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin targeted delivery of gene therapeutics.
    Juliano RL; Ming X; Nakagawa O; Xu R; Yoo H
    Theranostics; 2011 Mar; 1():211-9. PubMed ID: 21547161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.
    Senn C; Hangartner C; Moes S; Guerini D; Hofbauer KG
    Eur J Pharmacol; 2005 Oct; 522(1-3):30-7. PubMed ID: 16213482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid conjugated oligonucleotides: a useful strategy for delivery.
    Raouane M; Desmaële D; Urbinati G; Massaad-Massade L; Couvreur P
    Bioconjug Chem; 2012 Jun; 23(6):1091-104. PubMed ID: 22372953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA.
    Juliano RL
    Curr Opin Mol Ther; 2005 Apr; 7(2):132-6. PubMed ID: 15844620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent conjugation of oligonucleotides with cell-targeting ligands.
    Alam MR; Ming X; Nakagawa O; Jin J; Juliano RL
    Bioorg Med Chem; 2013 Oct; 21(20):6217-23. PubMed ID: 23777829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a future for cell-penetrating peptides in oligonucleotide delivery?
    Lee SH; Castagner B; Leroux JC
    Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological barriers to therapy with antisense and siRNA oligonucleotides.
    Juliano R; Bauman J; Kang H; Ming X
    Mol Pharm; 2009; 6(3):686-95. PubMed ID: 19397332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug delivery system of therapeutic oligonucleotides.
    Asami Y; Yoshioka K; Nishina K; Nagata T; Yokota T
    Drug Discov Ther; 2016; 10(5):256-262. PubMed ID: 27890899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.
    Toub N; Malvy C; Fattal E; Couvreur P
    Biomed Pharmacother; 2006 Nov; 60(9):607-20. PubMed ID: 16952435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes.
    Ming X; Sato K; Juliano RL
    J Control Release; 2011 Jul; 153(1):83-92. PubMed ID: 21571016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery systems for oligonucleotide therapeutics.
    Yu B; Zhao X; Lee LJ; Lee RJ
    AAPS J; 2009 Mar; 11(1):195-203. PubMed ID: 19296227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor.
    Ming X; Alam MR; Fisher M; Yan Y; Chen X; Juliano RL
    Nucleic Acids Res; 2010 Oct; 38(19):6567-76. PubMed ID: 20551131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.